1. Home
  2. CRSP vs MIR Comparison

CRSP vs MIR Comparison

Compare CRSP & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • MIR
  • Stock Information
  • Founded
  • CRSP 2013
  • MIR 2005
  • Country
  • CRSP Switzerland
  • MIR United States
  • Employees
  • CRSP N/A
  • MIR N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • MIR Industrial Machinery/Components
  • Sector
  • CRSP Health Care
  • MIR Technology
  • Exchange
  • CRSP Nasdaq
  • MIR Nasdaq
  • Market Cap
  • CRSP 4.9B
  • MIR 5.2B
  • IPO Year
  • CRSP 2016
  • MIR N/A
  • Fundamental
  • Price
  • CRSP $56.26
  • MIR $22.74
  • Analyst Decision
  • CRSP Buy
  • MIR Strong Buy
  • Analyst Count
  • CRSP 16
  • MIR 5
  • Target Price
  • CRSP $72.27
  • MIR $23.00
  • AVG Volume (30 Days)
  • CRSP 1.9M
  • MIR 4.5M
  • Earning Date
  • CRSP 11-04-2025
  • MIR 10-28-2025
  • Dividend Yield
  • CRSP N/A
  • MIR N/A
  • EPS Growth
  • CRSP N/A
  • MIR N/A
  • EPS
  • CRSP N/A
  • MIR 0.05
  • Revenue
  • CRSP $38,050,000.00
  • MIR $886,000,000.00
  • Revenue This Year
  • CRSP N/A
  • MIR $8.46
  • Revenue Next Year
  • CRSP $348.18
  • MIR $7.96
  • P/E Ratio
  • CRSP N/A
  • MIR $489.19
  • Revenue Growth
  • CRSP N/A
  • MIR 7.88
  • 52 Week Low
  • CRSP $30.04
  • MIR $9.45
  • 52 Week High
  • CRSP $71.13
  • MIR $23.58
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 54.66
  • MIR 60.32
  • Support Level
  • CRSP $51.63
  • MIR $20.98
  • Resistance Level
  • CRSP $55.59
  • MIR $23.58
  • Average True Range (ATR)
  • CRSP 2.06
  • MIR 0.76
  • MACD
  • CRSP 0.27
  • MIR 0.18
  • Stochastic Oscillator
  • CRSP 96.36
  • MIR 76.90

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About MIR Mirion Technologies Inc.

Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.

Share on Social Networks: